The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, bevacizumab and abraxane and ovarian cancer, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team.
Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.
These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
All recommendations are category 2A unless otherwise indicated. Days 1 — 2: Days 1 and 8: Days 1, 8, 15, 22, 29, and Weekly infusional LV5FU2 Days 1—5 and 8— Principals of Adjuvant Therapy 1.
Evidence suggests that North American patients may experience greater toxicity with capecitabine as well as with other fluoropyrimidines than European patients, and may require a lower dose of capecitabine.
Accessed May 8, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced rectal cancer. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and hour 5-fluorouracil continuous infusion regimens FOLFOX in pretreated metastatic colorectal cancer. Improved time to treatment failure with an intermittent oxaliplatin strategy: Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil FOLFOX in patients with metastatic colorectal cancer: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
N Engl J Med. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine RAISE: The Gruppo Oncologico Nord Ovest.
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single duke weight loss and surgery center fluoropyrimidine therapy for metastatic colorectal carcinoma. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer AVEX: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. Open-label phase Bevacizumab and abraxane and ovarian cancer trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer. Regorafenib dose optimization study ReDOS: PD-1 blockade in tumors with mismatch-repair deficiency, bevacizumab and abraxane and ovarian cancer.
CheckMate interim results [abstract]. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. Capecitabine as adjuvant treatment for stage III colon cancer. Repeat cycle every 2 weeks. Repeat every 2 weeks. Repeat cycle every 3 weeks. Repeat cycle every 8 weeks. Repeat cycle every bevacizumab and abraxane and ovarian cancer OR Day 1: Repeat cycle every week.
Vemurafenib mg orally twice daily. Regorafenib mg orally daily. Repeat cycle every 28 days. OR First Cycle Days Regorafenib 80mg orally daily Days Regorafenib mg orally daily Days Regorafenib mg orally daily Subsequent Cycles: Regorafenib mg orally daily Repeat cycle every 4 weeks. Repeat every 3 weeks. Repeat cycle every 3 weeks for 24 weeks.
Repeat cycle every 8 weeks for 4 cycles. Colorectal and Other GI Cancers. Data provided by MPR, bevacizumab and abraxane and ovarian cancer.